Incidence and Risk Factors of Hypophosphatemia in Patients with HIV Infection Receiving Tenofovir Disoproxil Fumarate; a real practice report from a Hospital Belonging to a Medical Service Department
Author(s): Praewa Netsuk, Jirapat Jullabath, Pornchita Lakum, Passara Phuetthanyakij, Pongsri Phuawaranukhroh, and Karunrat Tewthanom
This retrospective cross-sectional study aimed to estimate the incidence and risk factors of hypophosphatemia in patients receiving TDF-containing anti-HIV regimens. Data of patients with HIV infection who received TDF between July 1, 2018, and June 30, 2020, at a hospital belonging to a medical service department were reviewed. Data such as serum creatinine and serum phosphate levels were collected from medical records and electronic medical records and then transferred through a data record form. Hypophosphatemia was defined as serum phosphate value lower than 2.5 mg/dL. As a result, from 798 cases of patients with HIV infection who received TDF, 26 patients met the inclusion criteria and five patients had hypophosphatemia (19.2%), and the standard drug dose was used (300 mg/day) or was properly adjusted according to patients’ renal function. The median duration of TDF use was 10 (1–63) months. Other factors that may contribute to the development of hypophosphatemia are comorbidities and other drugs; there was one patient who used antacids longer than 1 week before onset of hypophosphatemia. This study may help develop a risk assessment tool for monitoring hypophosphatemia in patients who received TDF.